Fce 22250

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584402

CAS#: 84475-07-0

Description: Fce 22250 is a broad spectrum antibiotic active against Mycobacterium.

Chemical Structure

Fce 22250
CAS# 84475-07-0

Theoretical Analysis

MedKoo Cat#: 584402
Name: Fce 22250
CAS#: 84475-07-0
Chemical Formula: C44H58N4O12
Exact Mass: 834.4051
Molecular Weight: 834.964
Elemental Analysis: C, 63.29; H, 7.00; N, 6.71; O, 22.99

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Fce 22250; Fce-22250; Fce22250

IUPAC/Chemical Name: (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,26E)-2,15,17,29-Tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27-trioxo-26-{[(2E)-2-(1-piperidinylmethylene)hydrazino]methylene}-8,30-dioxa-24-azatetracyclo[,7.05,28]triaconta-1(28),2,4,9,19,21,25(29)-heptaen-13-yl acetate


InChi Code: InChI=1S/C44H58N4O12/c1-22-14-13-15-23(2)43(56)47-34-29(20-45-46-21-48-17-11-10-12-18-48)38(53)31-32(39(34)54)37(52)27(6)41-33(31)42(55)44(8,60-41)58-19-16-30(57-9)24(3)40(59-28(7)49)26(5)36(51)25(4)35(22)50/h13-16,19-22,24-26,30,35-36,40,45,50-52,54H,10-12,17-18H2,1-9H3,(H,47,56)/b14-13+,19-16+,23-15+,29-20+,46-21+/t22-,24+,25+,26+,30-,35-,36+,40+,44-/m0/s1

SMILES Code: CC(O[C@@H]([C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(C)/C(NC(/C1=C/N/N=C/N2CCCCC2)=C3O)=O)[C@H](C)[C@@H](OC)/C=C/O[C@](O4)(C)C(C5=C4C(C)=C(O)C3=C5C1=O)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 834.964 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Della Bruna C, Ungheri D, Sebben G, Sanfilippo A. Laboratory evaluation of a new long-acting 3-azinomethylrifamycin FCE 22250. J Antibiot (Tokyo). 1985 Jun;38(6):779-86. PubMed PMID: 3839503.

2: Ungheri D, Morvillo E, Sanfilippo A. [Activity of the ansamycins LM 427 and FCE 22250 on atypical mycobacteria in vitro]. G Ital Chemioter. 1983 May-Dec;30(2-3):97-100. Italian. PubMed PMID: 6329872.

3: Zanetti S, Ungheri D, Castellani Pastoris M, Fadda G. Comparative in vitro susceptibility studies of FCE 22250 and rifampicin on Legionella and Chlamydia trachomatis strains. Drugs Exp Clin Res. 1987;13(10):631-4. PubMed PMID: 3428127.

4: Amitani R, Kuze F. [New drugs against tuberculosis and nontuberculous mycobacterial infections: a review]. Kekkaku. 1994 Nov;69(11):711-7. Review. Japanese. PubMed PMID: 7837725.

5: Abeck D, Johnson AP, Alexander F, Korting HC, Ballard RC. In vitro activity of eight antimicrobial agents against non-penicillinase-producing gonococci isolated in Munich. Genitourin Med. 1988 Aug;64(4):233-4. PubMed PMID: 3139546; PubMed Central PMCID: PMC1194222.

6: Dickinson JM, Mitchison DA. In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Tubercle. 1987 Sep;68(3):183-93. PubMed PMID: 2834843.

7: Abeck D, Johnson AP, Dangor Y, Ballard RC. Antibiotic susceptibilities and plasmid profiles of Haemophilus ducreyi isolates from southern Africa. J Antimicrob Chemother. 1988 Oct;22(4):437-44. PubMed PMID: 3264554.

8: Kawahara S. [Chemotherapeutic agents under study]. Nihon Rinsho. 1998 Dec;56(12):3096-9. Review. Japanese. PubMed PMID: 9883617.

9: Vigevani A, Arlandini E, Ballabio M, Franceschi G, Gioia B, Vioglio S. Physico-chemical properties of FCE 22250, 3-(piperidinomethylazinomethyl)rifamycin SV, a new long-acting rifamycin. Farmaco Prat. 1985 May;40(5):131-40. PubMed PMID: 3839192.

10: Liu L, Wang ZY, Li D, Sun SL. [Disposition of 3-(N-piperidinomethylarino)methyl-rifamycin SV (FCE 22250) in rats]. Zhongguo Yao Li Xue Bao. 1991 Jan;12(1):58-62. Chinese. PubMed PMID: 1950587.